The UAE CGM market is expected to grow at a CAGR of 12.65%, from an initial value of US$3.645 million in 2021 to US$8.393 million by 2028.
Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.
Due to an increase in unhealthy lifestyles and other risk factors, diabetes is a fast-spreading illness that affects a significant portion of the population in the United Arab Emirates. The World Diabetes Federation estimates that the number of diabetics in the UAE would increase from 0.99 million in 2021 to 1.32 million in 2045. Individuals can reduce their risk of contracting this disease by adopting better lives and supporting expanding governmental measures. For patients hospitalized in hospitals with serious lung infections, controlling blood glucose levels become crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Also, throughout the forecast period, segment growth is anticipated to be fueled by the rising need for effective drug treatments for the treatment of diabetes.
Growing prevalence of Type-1 and Type-2 diabetes to surge growth.
As there is an increase in diabetic patients, there is an increase in continuous glucose monitoring systems. Also, there are various conveniences in testing blood glucose levels because of additional variables including technological improvements. Continuous glucose monitoring devices are one such development in blood glucose level monitoring. As a result, the market is anticipated to expand as more people with type 2 and type 1 diabetes use monitoring devices.
Technological advancements to surge growth.
Players in the global market are actively funding CGM research and technological development. The government's efforts to encourage local manufacturers to localize their production and to invite international companies in the healthcare sector to the nation assist the expansion of UAE continuous glucose monitoring devices. A further factor supporting the rise of the UAE glucometers market in the anticipated years is the general public's active investment in improved healthcare services and the need for modern monitoring tools that can help them maintain regular checks on their health issues.
Market Key Developments
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2021 | US$3.645 million |
| Market Size Value in 2028 | US$8.393 million |
| Growth Rate | CAGR of 12.65% from 2021 to 2028 |
| Base Year | 2021 |
| Forecast Period | 2023 – 2028 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Application and End-User Industry |
| Companies Covered | Abbott Laboratories, Medtronic plc, Dexcom, Inc., Sanofi, Roche Diabetes Care, Inc., Insulet Corporation, Novo Nordisk A/S, Becton, Dickinson, and Company |
| Customization Scope | Free report customization with purchase |
Segmentation: